IOVA Iovance Biotherapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
21:54
Jun 03
Jun 03
Buy IOVA into back-to-back catalysts — Australian TGA approval of Amtagvi in melanoma already in hand, with a Jefferies presentation tomorrow expected to show favorable early NSCLC cohort data, potentially expanding the addressable indication.
MED
00:56
Jun 02
Jun 02
Author explicitly says ABSI, ABCL, and IOVA are their bets on the digital biology narrative, which they expects to run hard.
MED
12:10
Jun 01
Jun 01
Buy IOVA on FDA IND approval for IOV-5001 targeting colorectal and breast cancers — two of the highest-prevalence tumor types globally — which meaningfully expands the addressable market for TIL therapy if trial data is positive.
MED
23:36
May 31
May 31
Buy IOVA ahead of upcoming TIL (tumor-infiltrating lymphocyte) therapy clinical data readout in NSCLC; speaker frames this as a personal directional bet on the cell therapy catalyst.
MED
18:12
May 29
May 29
Buy IOVA ahead of next week's ASCO presentation of NSCLC small-population durability data; author frames this as part of a broader "digital biology" rerating that is "only just beginning," suggesting upside catalyst from clinical readout.
MED
00:34
May 29
May 29
Buy IOVA for its unique FDA-approved TIL therapy, upcoming ASCO data, strong patent protection, and high probability of acquisition given scalability limitations and long cash runway.
MED
10:30
May 28
May 28
Buy IOVA as its TIL production patent protection (20+ years vs. 7–12yr for traditional biologics) creates a durable competitive moat; as the only FDA-approved TIL therapy, this patent advantage underpins a structurally superior long-term revenue base.
MED
20:48
May 27
May 27
First-hand account of IOVA tumor board presentations at top-10 oncology centers showing ~50% response rate in stage IV refractory pancreatic/cholangiocarcinoma, with deep durable responses in half of responders — substantive clinical data point.
MED
18:38
May 27
May 27
Buy IOVA — author has taken a large equity and options position at $3.60–$3.90, citing TIL (tumor-infiltrating lymphocyte) therapy as one of the best potential curative approaches in its category, with full DD forthcoming.
HIGH
20:18
May 23
May 23
IOVA presented TIL therapy data (with pembrolizumab) in stage IV refractory pancreatic and cholangiocarcinoma patients at a tumor board; partial response signal noted.
LOW
13:09
Apr 27
Apr 27
Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX, and IOVA, and expresses a forward-looking bearish view on ORKA.
HIGH
07:10
Apr 07
Apr 07
The author recommends buying IOVA stock on a price dip based on a thesis of sustained multi-year growth potential.
HIGH
About IOVA Analyst Coverage
Buzzberg tracks IOVA (Iovance Biotherapeutics, Inc.) across 3 sources. 8 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (67%). 12 total trade ideas tracked.